Latest Healthcare News

Enlitic has announced a strategic collaboration with GE HealthCare to deploy AI-driven technology that will transform the migration of medical imaging data, promising faster, more secure transitions and enhanced data quality for healthcare providers worldwide.

Ansell Limited has updated its FY25 interim dividend details, confirming a payment of USD 0.222 per share with an AUD equivalent of 0.3486, payable on March 6, 2025.

Biome Australia Limited has reported its first-ever net profit of $433,395 for the half-year ended December 2024, alongside a 47.4% increase in revenue driven by strong sales of its Activated Probiotics.

Cardiex Limited has confirmed to the ASX that it holds no undisclosed information explaining the recent spike in its share price, affirming full compliance with continuous disclosure rules.

Recce Pharmaceuticals reports strong Phase II results for its RECCE® 327 topical gel, achieving a 93% efficacy rate in treating serious skin infections and setting the stage for accelerated Phase 3 trials.

GWA Group Limited reported a 1.9% revenue increase and a 3.2% rise in normalized EBIT for the half year ended December 2024, alongside a 7.1% lift in its interim dividend, reflecting disciplined execution despite tough market conditions.

GWA Group Limited reported a 1.9% revenue increase and a 3.2% rise in normalised EBIT for the half year ended December 2024, supported by strong cash flow and operational discipline. The company declared a fully franked interim dividend of 7.5 cents per share, up 7.1%.

Osteopore Limited has drawn down A$2 million from the first tranche of its redeemable convertible notes, using the proceeds to repay existing loans and support ongoing business activities.

ResMed Inc. has updated the foreign exchange rate impacting its upcoming dividend payment to Australian CDI holders, reflecting currency volatility and tax treaty benefits.

Ecofibre Limited has restructured its Australian loan facilities, extending repayment terms and adjusting interest rates to support a more sustainable financial footing.

Wellnex Life Limited has locked in A$9 million in conditional commitments to support its proposed dual listing on the London Stock Exchange’s AIM market, alongside launching a 1:1 entitlement offer for existing shareholders.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.